Sponsored by ENSYSCE BIOSCIENCES
This activity is not certified for credit.
Date
Thursday, September 9
Start Time
3:40p
End Time
4:30p
Room
Castellana
Level 3
Program Description
In this session, sponsored by Ensysce Biosciences, Dr J. Gudin will lay out the evolution, benefits and challenges of opioid use. These agents have been used by man since 3,400 BC and remain a critical part in the treatment of severe and chronic pain. They carry liabilities that have caused the current crisis and COVID-19 has caused a sky rocket in opioid deaths – during Painweek we will lose 1110 patients from opioid-related deaths. The epidemic does not discriminate. Dr Gudin will explain who it affects and give statistics on the growing global crisis. He will suggest how we could improve care and the need for a next generation of opioid and give his thoughts on a new class of agent in clinical development.
Dr W Schmidt will then speak about his perspectives and experiences working on many opioids.
He will postulate that we may have a next generation of opioids in clinical development that could go beyond ADFs to provide the next level of abuse protection. This new class also offers the promise of an overdose-proof opioid – both agents representing a unique approach via sophisticated chemistry. Dr Schmidt will review promising preclinical and clinical data.
The CEO of Ensysce, Dr. L Kirkpatrick, will be on hand for a Q and A session when participants can ask questions.
Ensysce are excited to host this event and urge anyone interested in “generation 4” of opioids to attend.
Faculty
Jeff Gudin, MD
William Schmidt, PhD
Lynn Kirkpatrick, PhD
Pre-event Registration
No preregistration required
Refreshments will be served
Contact Name
Geoff Birkett
Contact Phone
(484) 467-1285
Contact email
[email protected]